| scholarly article | Q13442814 |
| P50 | author | Graham R. V. Hughes | Q73300356 |
| Ronald A. Asherson | Q73406057 | ||
| Eon Nigel Harris | Q73596049 | ||
| Azzudin E. Gharavi | Q73597624 | ||
| P2093 | author name string | Phillips G | |
| Sheehan N | |||
| Mercey D | |||
| P2860 | cites work | Livedo reticularis in systemic lupus erythematosus | Q28189894 |
| CEREBRO-VASCULAR LESIONS AND LIVEDO RETICULARIS | Q28201845 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| The association between the lupus anticoagulant and cerebral infarction in systemic lupus erythematosus | Q33446426 | ||
| Anticardiolipin antibodies: isotype distribution and phospholipid specificity | Q33456927 | ||
| Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus | Q33458388 | ||
| Cerebral infarction associated with lupus anticoagulants--preliminary report | Q33478161 | ||
| The Prosser-White oration 1983. Connective tissue disease and the skin | Q33478362 | ||
| Recurrent ischemic attacks in two young adults with lupus anticoagulant | Q34259693 | ||
| Livedo reticularis and cerebro-vascular disease | Q36717039 | ||
| Livedo reticularis and cerebrovascular lesions (Sneddon's syndrome). Clinical, radiological and pathological features in eight cases | Q39350092 | ||
| Recurrent transient global amnesia in a case with cerebrovascular lesions and livedo reticularis (sneddon syndrome) | Q39578541 | ||
| Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature | Q39848980 | ||
| Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologic findings in 57 cases, 1955–1977 | Q39884813 | ||
| Central retinal artery occlusion in Sneddon's disease associated with antiphospholipid antibodies | Q43676471 | ||
| Neuropsychiatric problems in systemic lupus erythematosus. | Q52119606 | ||
| [Livedo reticularis and cerebrovascular accidents]. | Q53979438 | ||
| Livedo reticularis and cerebro-vascular accidents | Q67726266 | ||
| Optic neuritis and myelopathy in systemic lupus erythematosus | Q70292559 | ||
| Livedo reticularis and neurological lesions | Q70365467 | ||
| [Livedo reticularis with neurological symptoms (author's transl)] | Q70411143 | ||
| Lupus anticoagulant in pregnancy | Q70474166 | ||
| The neurological manifestations of systemic lupus erythematosus | Q70861096 | ||
| [Neurological changes in livedo racemosa generalisata (Ehrmann). Case reports and review of the literature] | Q71552750 | ||
| Generalized racemose livedo and neurological lesions | Q71702191 | ||
| Livedo reticularis and cerebrovascular accidents | Q72433627 | ||
| Antiphospholipid antibodies in acute Guillain-Barré syndrome | Q72567741 | ||
| CEREBROVASCULAR ACCIDENTS AS THE INITIAL MAJOR MANIFESTATION OF LUPUS ERYTHEMATOSUS | Q76508514 | ||
| The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies | Q78981048 | ||
| Generalized racemose livedo with cerebrovascular lesions (Sneddon syndrome): an occlusive arteriolopathy due to proliferation and migration of medial smooth muscle cells | Q93569010 | ||
| The anticardiolipin syndrome | Q93670719 | ||
| Chorea and systemic lupus erythematosus with circulating anticoagulant. 3 cases | Q93677810 | ||
| Cerebral infarction in systemic lupus: association with anticardiolipin antibodies | Q93855660 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| antibody | Q79460 | ||
| dementia | Q83030 | ||
| multi-infarct dementia | Q69059904 | ||
| P304 | page(s) | 605-611 | |
| P577 | publication date | 1987-08-01 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies | |
| P478 | volume | 46 |
| Q36951385 | A review of neurological sequelae and cognitive deficits associated with antiphospholipid antibodies |
| Q40868635 | Abnormalities of hemostasis in ischemic stroke. |
| Q47988430 | Anticardiolipin antibodies in clinical conditions associated with a risk of thrombotic events |
| Q33423945 | Anticardiolipin antibodies in patients with autoimmune diseases: isotype distribution and clinical associations |
| Q35719544 | Anticardiolipin antibody |
| Q35356556 | Antiphospholipid antibodies and cardiovascular disease |
| Q41682862 | Antiphospholipid antibodies or not? The role of beta 2 glycoprotein 1 in autoantibody-mediated pregnancy loss |
| Q48245672 | Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes |
| Q70755530 | Antiphospholipid antibodies syndrome and cerebral ischemia |
| Q33328463 | Antiphospholipid antibody syndrome |
| Q38841201 | Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria? |
| Q36884847 | Antiphospholipid syndrome presenting as progressive neuropsychiatric disorders: two case reports |
| Q33557645 | Aortic occlusion in systemic lupus erythematosus associated with antiphospholipid antibodies |
| Q57089679 | Audiovestibular manifestations of the antiphospholipid syndrome |
| Q42442000 | Brain MR findings in patients with systemic lupus erythematosus with and without antiphospholipid antibody syndrome |
| Q37613091 | Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus |
| Q35625224 | CNS dysfunction in the antiphospholipid syndrome |
| Q72155864 | Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate |
| Q40529762 | Clinical and therapeutic aspects of the antiphospholipid syndrome |
| Q33497591 | Clinical manifestations of the aPL syndrome |
| Q40519206 | Clinicopathologic correlations of the antiphospholipid syndrome |
| Q37963790 | Cognitive dysfunction and antiphospholipid antibodies |
| Q77291197 | Conformationally altered beta 2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies |
| Q33567067 | Controversies in lupus: nervous system involvement |
| Q38660157 | Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE) |
| Q44921329 | Dementia with leukoencephalopathy in systemic lupus erythematosus |
| Q31166031 | Diagnosis and pathogenesis of CNS lupus |
| Q33628091 | Encephalopathy, deafness and blindness in young women: a distinct retinocochleocerebral arteriolopathy? |
| Q47578425 | High proportions of dementia among SLE patients: A big data analysis |
| Q69710811 | IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome |
| Q33392824 | Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients |
| Q33358817 | Longitudinal survey of anticardiolipin antibodies in systemic lupus erythematosus. Relationships with clinical manifestations and disease activity in an Italian series |
| Q33499900 | Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model |
| Q48249236 | Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer |
| Q33562378 | Neuropsychiatric lupus erythematosus, cerebral infarctions, and anticardiolipin antibodies. |
| Q35189295 | Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies |
| Q33503275 | Origin and pathogenesis of antiphospholipid antibodies |
| Q41203115 | Presence of Anticardiolipin Antibodies in Patients with Dementia: A Systematic Review and Meta-Analysis |
| Q33376853 | Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus erythematosus: a prospective study |
| Q48453807 | Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants |
| Q36681618 | Prevalence of anticardiolipin antibodies in the elderly British population |
| Q43837495 | Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics |
| Q86527461 | Prevention of recurrent stroke in patients with systemic lupus erythematosus or lupus anticoagulant |
| Q41032402 | Psychiatric disorder and cognitive impairment in SLE. |
| Q51773681 | Psychiatric manifestations as a primary symptom in antiphospholipid syndrome. |
| Q48008176 | Reversible dementia in systemic lupus erythematosus without antiphospholipid antibodies or cerebral infarction |
| Q37704593 | Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage |
| Q70172084 | Rheumatology |
| Q40971477 | Stroke is an emergency |
| Q70263826 | Systemic lupus erythematosus |
| Q72818973 | The antiphospholipid syndrome |
| Q33567393 | The antiphospholipid syndrome: a syndrome in evolution |
| Q35966558 | The role of antiphospholipid antibodies in stroke. |
| Q82010266 | Vascular dementia |
Search more.